Why did Bone Biologics' operating profit improve in Q2 2024?

Bone Biologics' operating profit improved in Q2 2024 due to **Revenue Growth** and **Cost Management**. 1. **Revenue Growth**: The company's Total Revenue increased to $2.2 million in Q2 2024, up from $1.6 million in the same period last year, indicating a growing market for their products. 2. **Cost Management**: Bone Biologics effectively managed their operating costs, as evidenced by the improvement in operating income to -$794,518 in Q2 2024, compared to the previous quarter's operating income of -$895,865. This improvement suggests better cost control or operational efficiency during the period. |code|Ticker|Name|Date|Operating Income|Total Revenue|market_code| |---|---|---|---|---|---|---| |BBLG|BBLG.O|Bone Biologics|2023 Q3|-2080354||186| |BBLG|BBLG.O|Bone Biologics|2023 Q4|-1159659||186| |BBLG|BBLG.O|Bone Biologics|2024 Q1|-903281||186| |BBLG|BBLG.O|Bone Biologics|2024 Q2|-794518||186| |code|Ticker|Name|Date|Free Cash Flow|Investing Cash Flow|Operating Cash Flow|Financing Cash Flow|market_code| |---|---|---|---|---|---|---|---|---| |BBLG|BBLG.O|Bone Biologics|2024 Q1|-1768774||-1303411|1504476|186| |BBLG|BBLG.O|Bone Biologics|2024 Q2|1118729|0|-895865|299|186|